Coronavirus (COVID-19)
Learn more
March 13, 2013
Location: The Hospital of Central Connecticut
A Phase II Trial of AMG 386 (IND#111071), A Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients with Persistent/Recurrent Carcinoma of the Endometrium.
Get the latest healthcare news directly in your inbox.
Sign up for text alerts / Text MoreLife to 31996.